Individualised Mapping in Persistent AF Ablation (IMAGE AF)
Primary Purpose
Persistent Atrial Fibrillation
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Pulmonary veins isolation + Cartofinder-guided ablation
Pulmonary veins isolation
Sponsored by
About this trial
This is an interventional treatment trial for Persistent Atrial Fibrillation focused on measuring persistent atrial fibrillation, catheter ablation, individualized mapping, focal activity, rotational activity
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years old
- Signed informed consent.
- Scheduled to undergo a clinically indicated, first-time catheter ablation procedure for the treatment of persistent atrial fibrillation.
- In atrial fibrillation at the time of the index procedure.
Exclusion Criteria:
- Paroxysmal atrial fibrillation.
- Previous ablation procedure for atrial fibrillation.
- Left ventricular ejection fraction < 45%
- Obesity with BMI > 35 kg/m2
- Congenital heart disease.
- Previous cardiac surgery with atriotomy.
- Previous left atrial appendage closure/ligation.
- Contraindications to systemic anticoagulation, catheter ablation, and/or general anaesthesia.
- Pregnancy
- Current enrolment in a study evaluating another device or drug.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
PVI only
PVI + IM
Arm Description
Patients in this arm will undergo only standard pulmonary veins isolation with radiofrequency (RF) energy to treat their AF.
Patients in this arm will undergo standard wide area circumferential pulmonary veins isolation along with radiofrequency energy and additional RF ablation guided by individualised mapping with Cartofinder to treat their AF.
Outcomes
Primary Outcome Measures
Freedom from atrial arrhythmia
Freedom from any atrial arrhythmia without the use of antiarrhythmic drugs
Secondary Outcome Measures
Freedom from atrial fibrillation
Freedom from atrial fibrillation without the use of antiarrhythmic drugs
Atrial fibrillation burden reduction
Reduction of the atrial fibrillation burden by 75% compared to baseline
Absolute atrial fibrillation burden
Absolute atrial fibrillation burden after a single, first-time ablative procedure guided by individualised mapping vs. standard approach.
Full Information
NCT ID
NCT05065112
First Posted
September 22, 2021
Last Updated
September 22, 2021
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT05065112
Brief Title
Individualised Mapping in Persistent AF Ablation
Acronym
IMAGE AF
Official Title
Individualised MApping-Guided Ablation to Improve Outcomes in pErsistent Atrial Fibrillation
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 2021 (Anticipated)
Primary Completion Date
November 2024 (Anticipated)
Study Completion Date
May 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Royal Brompton & Harefield NHS Foundation Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A clinical randomised trial to compare strategies for ablation in persistent and long-standing persistent atrial fibrillation comprising of two arms: pulmonary veins isolation (PVI) only and PVI + individualised mapping-guided ablation (Cartofinder, Biosense Webster Inc.)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Persistent Atrial Fibrillation
Keywords
persistent atrial fibrillation, catheter ablation, individualized mapping, focal activity, rotational activity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
212 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PVI only
Arm Type
Active Comparator
Arm Description
Patients in this arm will undergo only standard pulmonary veins isolation with radiofrequency (RF) energy to treat their AF.
Arm Title
PVI + IM
Arm Type
Experimental
Arm Description
Patients in this arm will undergo standard wide area circumferential pulmonary veins isolation along with radiofrequency energy and additional RF ablation guided by individualised mapping with Cartofinder to treat their AF.
Intervention Type
Procedure
Intervention Name(s)
Pulmonary veins isolation + Cartofinder-guided ablation
Intervention Description
The individualised mapping with Cartofinder intends to identify areas with the repetitive atrial activation patterns which are targeted with focal or linear ablation anchored on at least one end in an anatomical or electrical barrier.
Intervention Type
Procedure
Intervention Name(s)
Pulmonary veins isolation
Intervention Description
Wide area circumferential pulmonary veins isolation
Primary Outcome Measure Information:
Title
Freedom from atrial arrhythmia
Description
Freedom from any atrial arrhythmia without the use of antiarrhythmic drugs
Time Frame
12 monts
Secondary Outcome Measure Information:
Title
Freedom from atrial fibrillation
Description
Freedom from atrial fibrillation without the use of antiarrhythmic drugs
Time Frame
12 months
Title
Atrial fibrillation burden reduction
Description
Reduction of the atrial fibrillation burden by 75% compared to baseline
Time Frame
12 months
Title
Absolute atrial fibrillation burden
Description
Absolute atrial fibrillation burden after a single, first-time ablative procedure guided by individualised mapping vs. standard approach.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 18 years old
Signed informed consent.
Scheduled to undergo a clinically indicated, first-time catheter ablation procedure for the treatment of persistent atrial fibrillation.
In atrial fibrillation at the time of the index procedure.
Exclusion Criteria:
Paroxysmal atrial fibrillation.
Previous ablation procedure for atrial fibrillation.
Left ventricular ejection fraction < 45%
Obesity with BMI > 35 kg/m2
Congenital heart disease.
Previous cardiac surgery with atriotomy.
Previous left atrial appendage closure/ligation.
Contraindications to systemic anticoagulation, catheter ablation, and/or general anaesthesia.
Pregnancy
Current enrolment in a study evaluating another device or drug.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vias Markides, MD, FESC
Phone
020 7352 8121
Email
v.markides@imperial.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vias Markides, MD, FESC
Organizational Affiliation
Royal Brompton Hospital, London, UK
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Individualised Mapping in Persistent AF Ablation
We'll reach out to this number within 24 hrs